艾伯维公司宣布,其药物Maviret®(格卡瑞韦/哌仑他韦)已获得欧洲委员会的批准,用于治疗急性丙型肝炎病毒感染患者。
艾伯维公司宣布,其药物Maviret®(格卡瑞韦/哌仑他韦)已获得欧洲委员会的批准,用于治疗急性丙型肝炎病毒感染患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.